Dysregulated ADRB2 signaling is implicated in obesity and diabetes, and although β-arrestin’s metabolic roles are less studied, they hold potential for therapeutic strategies targeting metabolic disorders by improving energy metabolism and flexibility. Here, ADRB2 is linked to obesity disorder.